Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
41
Frequently Asked Questions
What is Market Cap of Contineum Therapeutics Inc. - Ordinary Shares - Class A?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Contineum Therapeutics Inc. - Ordinary Shares - Class A market cap is $316.03M.
What is the 52-week high for Contineum Therapeutics Inc. - Ordinary Shares - Class A?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Contineum Therapeutics Inc. - Ordinary Shares - Class A 52 week high is $20.24 as of September 24, 2025.
What is the 52-week low for Contineum Therapeutics Inc. - Ordinary Shares - Class A?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Contineum Therapeutics Inc. - Ordinary Shares - Class A 52 week low is $3.35 as of September 24, 2025.
What is Contineum Therapeutics Inc. - Ordinary Shares - Class A stock price today?
Contineum Therapeutics Inc. - Ordinary Shares - Class A stock price today is $11.06.
What was Contineum Therapeutics Inc. - Ordinary Shares - Class A stock price yesterday?
Contineum Therapeutics Inc. - Ordinary Shares - Class A stock price yesterday was $11.27.
What is the PE ratio of Contineum Therapeutics Inc. - Ordinary Shares - Class A?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Contineum Therapeutics Inc. - Ordinary Shares - Class A’s P/E ratio is -5.12.
What is the Price-to-Book ratio of Contineum Therapeutics Inc. - Ordinary Shares - Class A?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Contineum Therapeutics Inc. - Ordinary Shares - Class A P/B ratio is 1.7044.
What is the 50-day moving average of Contineum Therapeutics Inc. - Ordinary Shares - Class A?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Contineum Therapeutics Inc. - Ordinary Shares - Class A 50-day moving average is $8.33.
How many employess does Contineum Therapeutics Inc. - Ordinary Shares - Class A has?
Contineum Therapeutics Inc. - Ordinary Shares - Class A has 41 employees.
